MeiraGTx
Biotechnology ResearchEngland, United Kingdom201-500 Employees
MeiraGTx is a clinical-stage biotechnology company focused on genetic medicines, with end-to-end manufacturing capabilities spanning IND through commercial supply. It runs an internally developed platform including GMP plasmid production, two GMP viral vector facilities, and an in-house quality control hub for stability and release. The company emphasizes viral vector design and optimization alongside a riboswitch gene regulation technology that enables dose-responsive control of gene expression by oral small molecules. Its programs include delivering metabolic peptides such as GLP-1, GIP, Glucagon, and PYY via oral molecules, as well as cell therapies for oncology and autoimmune diseases, with initial targets in the eye, CNS, and salivary gland but broader applicability. Based in London, England, MeiraGTx, a mid-sized biotechnology company, collaborates with pharmaceutical and biotech developers seeking integrated genetic medicine manufacturing from early development to potential commercialization. A recent development noted in public disclosures includes reporting FDA Breakthrough Therapy Designation for AAV2-hAQP1, signaling progress in its ocular program.
1-888-653-2347 
support@leadiq.com 
